Reduction of obesity-associated white adipose tissue inflammation by rosiglitazone is associated with reduced non-alcoholic fatty liver disease in LDLr-deficient mice

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Mulder, Petra ^a,b   Morrison, Martine C ^a   Verschuren, Lars ^a   Liang, Wen ^a   Van Bockel, J Hajo ^b   Kooistra, Teake ^a   Wielinga, Peter Y ^a   Kleemann, Robert ^a,b  

^a TNO   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; LOW DENSITY LIPOPROTEIN RECEPTOR; ROSIGLITAZONE;

ANIMAL; DEFICIENCY; GENETICS; INFLAMMATION; KNOCKOUT MOUSE; MALE; METABOLISM; MOUSE; NONALCOHOLIC FATTY LIVER; OBESITY; PATHOLOGY; WHITE ADIPOSE TISSUE;

ADIPOSE TISSUE, WHITE; ANIMALS; INFLAMMATION; MALE; MICE; MICE, KNOCKOUT; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; RECEPTORS, LDL; THIAZOLIDINEDIONES;

EID: 84983247516     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep31542     Document Type: Article

References (45)

1. Ng, M. et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 384, 766-781 (2014).
2. Hotamisligil, G. S. Inflammation and metabolic disorders. Nature 444, 860-867 (2006).
3. Lumeng, C. N. & Saltiel, A. R. Inflammatory links between obesity and metabolic disease. J Clin Invest 121, 2111-2117 (2011).
4. Tilg, H. & Moschen, A. R. Insulin resistance, inflammation, and non-alcoholic fatty liver disease. Trends Endocrinol Metab 19, 371-379 (2008).
5. Mulder, P. et al. Surgical removal of inflamed epididymal white adipose tissue attenuates the development of non-alcoholic steatohepatitis in obesity. Int J Obes (Lond) (2015).
6. Bays, H. E. et al. Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity. Expert Rev Cardiovasc Ther 6, 343-368 (2008).
7. Skurk, T., Alberti-Huber, C., Herder, C. & Hauner, H. Relationship between adipocyte size and adipokine expression and secretion. J Clin Endocrinol Metab 92, 1023-1033 (2007).
8. Cinti, S. et al. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res 46, 2347-2355 (2005).
9. Fabbrini, E., Sullivan, S. & Klein, S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 51, 679-689 (2010).
10. Kolak, M. et al. Adipose tissue inflammation and increased ceramide content characterize subjects with high liver fat content independent of obesity. Diabetes 56, 1960-1968 (2007).
11. Mirza, M. S. Obesity, Visceral Fat, and NAFLD: Querying the Role of Adipokines in the Progression of Nonalcoholic Fatty Liver Disease. ISRN Gastroenterol 2011, 592404 (2011).
12. Tilg, H. & Moschen, A. R. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 6, 772-783 (2006).
13. Olefsky, J. M. & Glass, C. K. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol 72, 219-246 (2010).
14. Kolak, M. et al. Effects of chronic rosiglitazone therapy on gene expression in human adipose tissue in vivo in patients with type 2 diabetes. J Clin Endocrinol Metab 92, 720-724 (2007).
15. Xu, H. et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 112, 1821-1830 (2003).
16. Nguyen, M. T. et al. Regulation of chemokine and chemokine receptor expression by PPARgamma in adipocytes and macrophages. PLoS One 7, e34976 (2012).
17. Stienstra, R. et al. Peroxisome proliferator-activated receptor gamma activation promotes infiltration of alternatively activated macrophages into adipose tissue. J Biol Chem 283, 22620-22627 (2008).
18. Tiniakos, D. G., Vos, M. B. & Brunt, E. M. Nonalcoholic fatty liver disease: pathology and pathogenesis. Annu Rev Pathol 5, 145-171 (2010).
19. Moylan, C. A. et al. Hepatic gene expression profiles differentiate presymptomatic patients with mild versus severe nonalcoholic fatty liver disease. Hepatology 59, 471-482 (2014).
20. Liang, W. et al. Metabolically induced liver inflammation leads to NASH and differs from LPS- or IL-1beta-induced chronic inflammation. Lab Invest 94, 491-502 (2014).
21. Moran-Salvador, E. et al. Role for PPARgamma in obesity-induced hepatic steatosis as determined by hepatocyte- and macrophagespecific conditional knockouts. FASEB J 25, 2538-2550 (2011).
22. He, W. et al. Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle. Proc Natl Acad Sci USA 100, 15712-15717 (2003).
23. Gavrilova, O. et al. Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J Biol Chem 278, 34268-34276 (2003).
24. Gupte, A. A. et al. Rosiglitazone attenuates age- and diet-associated nonalcoholic steatohepatitis in male low-density lipoprotein receptor knockout mice. Hepatology 52, 2001-2011 (2010).
25. Wouters, K. et al. Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis. Hepatology 48, 474-486 (2008).
26. Funke, A. et al. Cholesterol-induced hepatic inflammation does not contribute to the development of insulin resistance in male LDL receptor knockout mice. Atherosclerosis 232, 390-396 (2014).
27. Caesar, R. et al. A combined transcriptomics and lipidomics analysis of subcutaneous, epididymal and mesenteric adipose tissue reveals marked functional differences. PLoS One 5, e11525 (2010).
28. O'Connell, J. et al. The relationship of omental and subcutaneous adipocyte size to metabolic disease in severe obesity. PLoS One 5, e9997 (2010).
29. Boden, G., Cheung, P., Mozzoli, M. & Fried, S. K. Effect of thiazolidinediones on glucose and fatty acid metabolism in patients with type 2 diabetes. Metabolism 52, 753-759 (2003).
30. McLaughlin, T. M. et al. Pioglitazone increases the proportion of small cells in human abdominal subcutaneous adipose tissue. Obesity (Silver Spring) 18, 926-931 (2010).
31. Smith, U. & Hammarstedt, A. Antagonistic effects of thiazolidinediones and cytokines in lipotoxicity. Biochim Biophys Acta 1801, 377-380 (2010).
32. Kim, H. J. et al. Depot-specific regulation of perilipin by rosiglitazone in a diabetic animal model. Metabolism 56, 676-685 (2007).
33. Neuschwander-Tetri, B. A., Brunt, E. M., Wehmeier, K. R., Oliver, D. & Bacon, B. R. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 38, 1008-1017 (2003).
34. Belfort, R. et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 355, 2297-2307 (2006).
35. Cancello, R. et al. Increased infiltration of macrophages in omental adipose tissue is associated with marked hepatic lesions in morbid human obesity. Diabetes 55, 1554-1561 (2006).
36. du Plessis, J. et al. Association of Adipose Tissue Inflammation With Histologic Severity of Nonalcoholic Fatty Liver Disease. Gastroenterology 149, 635-648 e614 (2015).
37. Prieur, X. et al. Differential lipid partitioning between adipocytes and tissue macrophages modulates macrophage lipotoxicity and M2/M1 polarization in obese mice. Diabetes 60, 797-809 (2011).
38. Marra, F. & Lotersztajn, S. Pathophysiology of NASH: perspectives for a targeted treatment. Curr Pharm Des 19, 5250-5269 (2013).
39. Tilg, H. The role of cytokines in non-alcoholic fatty liver disease. Dig Dis 28, 179-185 (2010).
40. Shi, H. et al. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 116, 3015-3025 (2006).
41. de Almeida, I. T., Cortez-Pinto, H., Fidalgo, G., Rodrigues, D. & Camilo, M. E. Plasma total and free fatty acids composition in human non-alcoholic steatohepatitis. Clin Nutr 21, 219-223 (2002).
42. Wobser, H. et al. Lipid accumulation in hepatocytes induces fibrogenic activation of hepatic stellate cells. Cell Res 19, 996-1005 (2009).
43. Radonjic, M. et al. Differential effects of drug interventions and dietary lifestyle in developing type 2 diabetes and complications: a systems biology analysis in LDLr-/- mice. PLoS One 8, e56122 (2013).
44. Liang, W. et al. Establishment of a general NAFLD scoring system for rodent models and comparison to human liver pathology. PLoS One 9, e115922 (2014).
45. Liang, W. et al. Coordinated and interactive expression of genes of lipid metabolism and inflammation in adipose tissue and liver during metabolic overload. PLoS One 8, e75290 (2013).